Seres Therapeutics (MCRB) Return on Sales (2016 - 2025)
Historic Return on Sales for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2024 value amounting to 1865.25%.
- Seres Therapeutics' Return on Sales rose 18873100.0% to 1865.25% in Q3 2024 from the same period last year, while for Sep 2024 it was 1865.25%, marking a year-over-year increase of 18655000.0%. This contributed to the annual value of 0.6% for FY2023, which is 99400.0% up from last year.
- Seres Therapeutics' Return on Sales amounted to 1865.25% in Q3 2024, which was up 18873100.0% from 72.93% recorded in Q2 2024.
- In the past 5 years, Seres Therapeutics' Return on Sales registered a high of 1865.25% during Q3 2024, and its lowest value of 136.94% during Q1 2023.
- Over the past 5 years, Seres Therapeutics' median Return on Sales value was 6.88% (recorded in 2021), while the average stood at 72.17%.
- Per our database at Business Quant, Seres Therapeutics' Return on Sales plummeted by -997900bps in 2023 and then soared by 18873100bps in 2024.
- Seres Therapeutics' Return on Sales (Quarter) stood at 1.03% in 2020, then crashed by -570bps to 6.88% in 2021, then soared by 67bps to 2.25% in 2022, then crashed by -4429bps to 102.05% in 2023, then skyrocketed by 1928bps to 1865.25% in 2024.
- Its Return on Sales was 1865.25% in Q3 2024, compared to 72.93% in Q2 2024 and 0.22% in Q1 2024.